Larenkov Anton, Mitrofanov Iurii, Rakhimov Marat
State Research Center-Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Zhivopisnaya Str., Bld. 46, 123098 Moscow, Russia.
Pharmaceutics. 2024 Nov 30;16(12):1535. doi: 10.3390/pharmaceutics16121535.
Radiochemical purity is a key criterion for the quality of radiopharmaceuticals used in clinical practice. The joint improvement of analytical methods capable of identifying related radiochemical impurities and determining the actual radiochemical purity, as well as the improvement of synthesis methods to minimize the formation of possible radiochemical impurities, is integral to the implementation of high-tech nuclear medicine procedures. PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for prostate cancer, and [Lu]Lu-PSMA-617 and [Lu]Lu-PSMA have achieved global recognition as viable radiopharmaceuticals. Recently, it was shown that specific radiochemical impurities can form during the synthesis of [Lu]Lu-PSMA-617 because of a spontaneous, thermally mediated condensation of the Glu-C(O)-Lys fragment, resulting in the formation of three different cyclic forms (with no affinity for PSMA). During this study, we identified another impurity, a product of detachment of the Glu-CO fragment from PSMA-617, caused by heating. The total content of all four thermally mediated degradation products may reach 9-11% during classical incubation for 30 min at 95 °C, reducing the radiochemical purity to an unacceptable level (albeit with high levels of radiochemical conversion). It is reasonable to assume that the formation of similar impurities is characteristic of all PSMA-specific vectors that contain Glu-C(O)-Lys pharmacophores. Because the formation of these impurities directly depends on the temperature and incubation time, to reduce their content in the reaction mixture at the end of the synthesis, it is necessary to select conditions to achieve a high level of radiochemical conversion for the minimum possible time and/or at the minimum sufficient temperature.
In this study, using [Lu]Lu-PSMA-617 as an example, we evaluated the efficiency of alternative methods of synthesis with microwave heating and co-solvent (ethanol) addition to ensure radiochemical yield and radiochemical purity in the shortest possible time and at the minimum necessary and sufficient synthesis temperature.
Both approaches achieved a significant reduction in the impurities content, while achieving satisfactory synthesis yields in a short time. In addition to improving the synthesis parameters and radiochemical purity, the use of microwave heating and the addition of ethanol reduces the negative influence of other auxiliaries on labeling kinetics. Notably, the addition of ethanol under certain conditions allowed [Lu]Lu-PSMA-617 to be synthesized at room temperature for only 10 min. This makes it possible to achieve exceptionally high real radiochemical purity of the preparations, determined only by the quality of the original precursor. The approaches considered in this study can be successfully applied to improve the synthesis process and quality parameters of the finished product, both for known radiopharmaceuticals and for those under development.
放射化学纯度是临床实践中使用的放射性药物质量的关键标准。能够识别相关放射化学杂质并确定实际放射化学纯度的分析方法的联合改进,以及改进合成方法以尽量减少可能的放射化学杂质的形成,对于实施高科技核医学程序至关重要。用镥 - 177进行的前列腺特异性膜抗原(PSMA)靶向放射性核素治疗已成为前列腺癌的一种有效治疗选择,[镥 - 177]镥 - PSMA - 617和[镥 - 177]镥 - PSMA已作为可行的放射性药物获得全球认可。最近研究表明,在[镥 - 177]镥 - PSMA - 617的合成过程中,由于Glu - C(O) - Lys片段的自发热介导缩合,会形成特定的放射化学杂质,导致形成三种不同的环状形式(对PSMA无亲和力)。在本研究中,我们鉴定出另一种杂质,它是由加热导致的Glu - CO片段从PSMA - 617上脱落的产物。在95℃经典孵育30分钟的过程中,所有四种热介导降解产物的总含量可能达到9 - 11%,从而将放射化学纯度降低到不可接受的水平(尽管放射化学转化率很高)。可以合理推测,所有含有Glu - C(O) - Lys药效基团的PSMA特异性载体都具有形成类似杂质的特性。由于这些杂质的形成直接取决于温度和孵育时间,为了在合成结束时降低反应混合物中它们的含量,有必要选择条件,以在尽可能短的时间内和/或在最低足够温度下实现高水平的放射化学转化。
在本研究中,以[镥 - 177]镥 - PSMA - 617为例,我们评估了微波加热和添加共溶剂(乙醇)的替代合成方法的效率,以确保在尽可能短的时间内和最低必要且足够的合成温度下获得放射化学产率和放射化学纯度。
两种方法都显著降低了杂质含量,同时在短时间内获得了令人满意的合成产率。除了改善合成参数和放射化学纯度外,使用微波加热和添加乙醇还减少了其他助剂对标记动力学的负面影响。值得注意的是,在某些条件下添加乙醇可使[镥 - 177]镥 - PSMA - 617仅在室温下合成10分钟。这使得仅根据原始前体的质量就能实现制剂极高的实际放射化学纯度。本研究中考虑的方法可成功应用于改进已知放射性药物和正在研发的放射性药物的合成过程和成品质量参数。